Info-starved patients want more from docs, survey says

Share this article:

Doctors aren't doing enough to educate patients about disease management, leaving patients to fend for themselves, according to a MedTera study conducted in September.

Of the 7,028 survey respondents, 95% indicated that they are looking for more comprehensive information about disease management, and 77% said they hadn't received any written information about their illness or medications directly from the physician, according to the survey.

High percentiles of the patients surveyed said specific types of information are “very much” or “extremely” valuable, including:

  • Details on the importance of follow-ups and tests (94%)
  • Dietary recommendations based on condition (86%)
  • Online resources to help manage a condition (84%)
  • Changes in lifestyle that might be required (82%)
  • Information on medications and potential side effects (78%)

Dave Duplay, president of MedTera, said the data reveals “a tremendous opportunity for pharma to get out in front of this issue.” New survey data around the kinds of tools patients consider most useful will be released in early 2011. The survey is a result of MedTera's internal findings suggesting that 29%-71% of newly diagnosed patients with chronic illnesses were going off their medications within the first 30 days, Duplay said.

MedTera, a one-year-old subsidiary of Structural Graphics, is an integrated marketing firm that creates print and dimensional materials for patients, delivered to doctors by sales reps and through the mail. The materials direct patients to digital assets online, Duplay said. 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...